DDInter923 DDInter458
Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α, infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α. Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Infliximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} (Compound) binds {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Cyclosporine
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etonogestrel
Etonogestrel {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Cyclosporine
Infliximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Cyclosporine
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etonogestrel
Etonogestrel {u} (Compound) causes {v} (Side Effect) Abnormal vision
Abnormal vision {u} (Side Effect) is caused by {v} (Compound) Cyclosporine
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Procainamide
Procainamide {u} (Compound) binds {v} (Gene) DNMT1
DNMT1 {u} (Gene) is downregulated by {v} (Compound) Cyclosporine
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norethisterone
Norethisterone {u} (Compound) upregulates {v} (Gene) GOLGB1
GOLGB1 {u} (Gene) is upregulated by {v} (Compound) Cyclosporine
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norethisterone
Norethisterone {u} (Compound) downregulates {v} (Gene) ST7
ST7 {u} (Gene) is upregulated by {v} (Compound) Cyclosporine
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapsone
Dapsone {u} (Compound) treats {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is treated by {v} (Compound) Cyclosporine
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nicardipine
Nicardipine {u} (Compound) downregulates {v} (Gene) PPP2R5E
PPP2R5E {u} (Gene) is downregulated by {v} (Compound) Cyclosporine
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amiodarone
Amiodarone {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
P-Glycoprotein Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Cyclosporine
Infliximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E (Compound) binds HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Cyclosporine (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Etonogestrel and Etonogestrel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cyclosporine (Compound)
Infliximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Cyclosporine (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Etonogestrel and Etonogestrel (Compound) causes Abnormal vision (Side Effect) and Abnormal vision (Side Effect) is caused by Cyclosporine (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Procainamide and Procainamide (Compound) binds DNMT1 (Gene) and DNMT1 (Gene) is downregulated by Cyclosporine (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone (Compound) upregulates GOLGB1 (Gene) and GOLGB1 (Gene) is upregulated by Cyclosporine (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone (Compound) downregulates ST7 (Gene) and ST7 (Gene) is upregulated by Cyclosporine (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone (Compound) treats systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is treated by Cyclosporine (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Nicardipine and Nicardipine (Compound) downregulates PPP2R5E (Gene) and PPP2R5E (Gene) is downregulated by Cyclosporine (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class) and P-Glycoprotein Inhibitors (Pharmacologic Class) includes Cyclosporine (Compound)